45 results about "Post immunization" patented technology

The invention provides a novel ecological feed capable of preventing multiple grass-bream diseases, the novel ecological feed comprises a feed matrix and an ecological feed leavening agent, and the ecological feed leavening agent comprises probiotics with surface expression antigens, the antigen is any one or more of a grass carp reovirus antigen, a flavobacterium johnsonii antigen, an aeromonas veronii antigen and a clonorchis sinensis antigen. The novel ecological feed with a disease-resistant function in a parabramis pekinensis breeding mode is prepared for the first time, the resistance of the parabramis pekinensis to various pathogens can be enhanced, and the survival rate of the parabramis pekinensis in the disease attack peak period can be increased by 50% or above after immunization. An oral immunization mode is adopted and can be completed in the feeding process, and the immunization and breeding cost is greatly saved.

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The invention is applicable to the field of genetic engineering, and provides a mycobacterium tuberculosis Mce1A-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis Mce1A-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis Mce1A protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis Mce1A-LS protein nanoparticle is shown as SEQ ID NO: 2 in a sequence table. The Mce1A-LS protein nanoparticle provided by the invention is high in immunogenicity, the protein Mce1A with high immunogenicity can induce to generate a synergistic immune effect and is high in safety, and the expressed fusion protein is non-toxic and harmless, so that the biosafety is high, in addition, the immune effect of the Mce1A-LS protein nanoparticle is good, and after the Mce1A-LS protein nanoparticle is used for immunizing a mouse, the immunogenicity of the Mce1A-LS protein nanoparticle is greatly improved. Strong body fluid and / or cellular immune response can be generated, which indicates that after immunization, a specific immune effect can be generated in a mouse body.

The present application relates to the technical field of veterinary biological products, in particular to application of oridonin in preparation of poultry vaccine adjuvant. The poultry vaccine adjuvant is composed of oridonin, solvent and buffer. Experiments prove that after mixing the poultry vaccine adjuvant with poultry inactivated vaccine (such as Newcastle disease vaccine) for immunization, the humoral immune level of poultry can be significantly improved (HI titer of 21d after the second immunization is increased by more than 1.5 log2), and the secretion level of specific IgY (systemic immunity) and IgA (mucosal immunity) in serum can be extremely significantly up-regulated, and the high level of antibody is maintained for more than 4 weeks longer than that of the conventional vaccine group. Compared with commercial adjuvant ISA 201, the present application has better immune enhancement activity, high safety, no adverse reaction at injection site, and wide clinical application prospect.

The application discloses a preparation method of a novel inhalable anthrax component vaccine based on a mutant strain of anthrax bacillus, and relates to the technical field of immunology medicine. The application provides a mutant strain of anthrax bacillus, and a mutant strain A16R-5.1 with six extracellular protease activity related genes deleted. The vaccine is extracted from the culture supernatant of anthrax prepared by using the mutant strain A16R-5.1, and can induce strong humoral, cellular and mucosal immune responses after immunization, can resist the invasion of anthrax spores, and can neutralize anthrax toxin in an in-vitro experiment.

The invention relates to a recombinant rabies virus. The recombinant rabies virus is obtained by inserting an antigen gene of feline calicivirus and an antigen gene of feline herpes virus into a genome of a rabies virus attenuated strain. The triple inactivated vaccine for preventing and treating the feline calicivirus disease, the feline herpes virus disease and / or the rabies is prepared based on the recombinant rabies virus, and after the triple inactivated vaccine is used for immunizing cats, neutralizing antibodies aiming at the feline calicivirus disease, the feline herpes virus disease and the rabies virus can be effectively induced and generated; the simultaneous immunization on the three viruses is realized.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus E2 protein and application, and relates to the technical field of biology.The recombinant E2 protein provided by the application successfully realizes high-level expression of the E2 protein by removing the transmembrane region of the E2 protein and using the 18aa signal peptide of the E2 protein itself and a pig albumin signal peptide.The recombinant PRV expressing the classical swine fever virus (CSFV) E2 protein can induce E2 antibodies and cellular immunity after immunization of mice.The recombinant pseudorabies virus strain provided by the application can be used as a bivalent vaccine for preventing CSFV and PRV infection.

This application discloses a recombinant hemagglutinin protein, its uses, expression methods, and subunit vaccines, belonging to the field of biomedical technology. The technical solution is as follows: a recombinant hemagglutinin protein, obtained by removing the transmembrane and intracellular regions of the HA protein sequence of the H7N9-235 strain and fusing a T4-foldon sequence at the C-terminus; or by retaining the full-length sequence of the HA protein of the H7N9-235 strain. The amino acid sequence of the recombinant hemagglutinin protein is shown in SEQ ID NO.1 or SEQ ID NO.2. The application also discloses a recombinant hemagglutinin protein with good immunogenicity and medical prospects based on the H7N9 strain. Furthermore, when a subunit vaccine is prepared using the recombinant hemagglutinin protein with the transmembrane and intracellular regions removed, the immunogenicity after secondary immunization is significantly enhanced.

The application discloses an egg yolk antibody against Nocardiosis and a preparation method and application thereof, and relates to the technical field of biological medicines. A light chain sequence of the egg yolk antibody comprises a sequence shown in SEQ ID NO. 1, and a heavy chain sequence comprises a sequence shown in SEQ ID NO. 2. The application expands culture of pathogenic bacteria Nocardia, prepares an inactivated bacterin vaccine, and immunizes hens, so that the hens produce egg yolk antibodies against Nocardia through an immune response. After immunization, the application collects eggs, extracts the egg yolk antibodies against Nocardiosis from egg yolk by using a water dilution method. It is verified that the egg yolk antibodies have a strong binding capacity with Nocardia, can effectively inhibit Nocardia, and the titer can reach 1:64000 at the highest.

The application belongs to the technical field of molecular biology, and particularly relates to an anti-CD28 nanobody and a preparation method and application thereof. The anti-CD28 nanobody provided by the application is prepared in the following manner: constructing a CD28 antigen to immunize a llama, constructing a phage library to the PBMC of the immunized llama, screening the phage library, selecting correct sequences to construct and express and purify, and finally obtaining the anti-CD28 nanobody through cell function detection screening. The nanobody provided by the application has specific recognition and binding capacity for CD28, has the advantages of high specificity, high sensitivity and the like, effectively reduces the development and production cost of the CD28 antibody, and shortens the expression time of the antibody.

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

The invention relates to the technical field of drug delivery and tumor immunotherapy, and discloses nested lipid nanoparticles for immunotherapy synergy as well as a preparation method and application of the nested lipid nanoparticles. The nLNP has a double-layer nested structure with an inner layer carrying Hsc70 mRNA and an outer layer carrying an STING agonist MSA-2 prodrug, and an inner layer nitrogen stacking group and an outer layer DBCO group are connected through a click reaction to realize tumor pre-targeting enrichment; the pH response lipid on the outer layer is dissociated preferentially in a slightly acidic environment, firstly releases an MSA-2 prodrug to activate innate immunity, and then releases Hsc70 mRNA to reverse PD-L1 related drug resistance, so that the curative effect of the immune checkpoint inhibitor is synergistically enhanced. The preparation provided by the invention has the advantages of strong targeting property, controllable release and good safety, and is suitable for drugs or pharmaceutical compositions for tumor immunotherapy synergy.

This invention discloses the construction of a Toxoplasma gondii progesterone-responsive kinase-deficient strain and its application as a live attenuated vaccine. The Toxoplasma gondii progesterone-responsive kinase-deficient strain is derived from Toxoplasma gondii RHΔ... ku80 As a maternal strain, the gene-editing technology was used to knock out the enzyme encoding progesterone-responsive kinase. prk The gene-deleted strain was named RHΔ ku80 Δ prk Experiments have shown that RHΔ ku80 Δ prk The virulence of the strain was significantly reduced, and immunized mice showed good immunoprotection against acute infection with highly virulent and moderately virulent Toxoplasma gondii strains, and significantly inhibited brain cyst formation in a chronic infection model. Therefore, RHΔ ku80 Δ prk This invention has potential application value as a live attenuated vaccine against Toxoplasma gondii. It has significant application prospects.

The application provides a hybridoma cell strain secreting a monoclonal antibody against a alginate mannuronic acid tetrasaccharide epitope, a monoclonal antibody and application. In order to enhance the immunogenicity of the mannuronic acid tetrasaccharide, a glycoconjugate KLH-1 is used as an immunogen to inject and immunize a mouse, so that the mouse is stimulated to produce a specific immune response against the mannuronic acid tetrasaccharide epitope, then spleen cells of the immunized mouse are fused with myeloma cells, and after screening, an initial hybridoma cell strain is obtained; then after subcloning and specific screening, a hybridoma cell strain capable of stably secreting a monoclonal antibody of the target mannuronic acid tetrasaccharide epitope in alginate is obtained, and a monoclonal ascites antibody is further obtained. The monoclonal ascites antibody shows specific recognition and combination ability for pseudomonas aeruginosa, and the combination activity is related to the expression level of alginate on the surface of the bacteria. Therefore, the monoclonal ascites antibody can be used as a precise detection and diagnosis tool for pseudomonas aeruginosa, and can also be applied to the antibacterial treatment of pseudomonas aeruginosa infection.

The present application relates to the field of immunoassay technology, and provides a myclobutanil hapten, antigen, antibody and preparation method and application. The present application introduces an active group at the meta position of the chlorine atom on the benzene ring of myclobutanil. Compared with the existing hapten, the hapten provided by the present application completely simulates the structure of myclobutanil, and enhances the immunogenicity of the antigen. The antigen provided by the present application has strong immunogenicity after being coupled with a carrier protein. After injection immunization of mice, the titer of the produced antibody is 5.0x10 4 , the half-inhibitory concentration (IC 50 ) is about 50 ppb, and the minimum detection limit of colloidal gold for myclobutanil in dry tobacco leaf samples is about 2.5 μg / g.

The application provides a kind of construction and application of PRRSV live vector vaccine strain of recombination expression PEDV S protein receptor RBD domain, and the results show that the dominant antigen region of PEDV S protein RBD function domain can be expressed in the recombination virus rHuN4-F112-SRBD1 rescued, and the biological characteristics of recombination virus are similar to parent virus.The nucleotide sequence of SRBD1 gene introduced in each generation of recombination virus and the amino acid sequence encoded thereby are not deleted or mutated, and the IFA and Western Blot detection results show that the SRBD1 gene introduced in different generations of recombination virus rHuN4-F112-SRBD1 can be stably expressed, and does not affect the expression of parent virus itself protein, indicating that the recombination virus rHuN4-F112-SRBD1 strain has genetic stability.The immunogenicity analysis of recombination virus rHuN4-F112-SRBD1 shows that the recombination virus rHuN4-F112-SRBD1 strain can induce specific antibodies against PEDV S protein and PRRSV2 in piglets after immunization, and the antibodies induced have neutralizing effect on PEDV epidemic strain, and can be used for the development and development of PRRS and PED novel genetic engineering vaccine.

The application belongs to the field of marine biotechnology, and particularly relates to natural polysaccharide-quaternized chitosan nanoparticles with immune stimulation and preparation and application thereof. The nanoparticles formed by natural polysaccharide with negative charge and quaternized chitosan with positive charge are obtained by polyelectrolyte complexation, the particle size is 316.4 nm, and the potential is 31.1 mV; the quaternized chitosan with positive charge and the natural polysaccharide with negative charge are mixed in a mass ratio of 6.25-10:1-4. After immunization of mice, the secretion amount of immunoglobulin IgG and immune factors in the mice is determined, which shows that the nanoparticles have good immune activity, thereby playing an effect in vaccine adjuvant. The application provides a method and guidance for the research on natural polysaccharide and chitosan derivatives as immune adjuvants in recent years.

The invention belongs to the technical field of biology, relates to a haemophilus parasuis subunit vaccine as well as a preparation method and application thereof, and provides a haemophilus parasuis antigen combination which comprises a recombinant P3 protein and a recombinant P5 protein, the recombinant P3 protein is coded by a sequence shown in SEQ ID No.1, the recombinant P5 protein is coded by a sequence shown in SEQ ID No.2, and the recombinant P3 protein is coded by a sequence shown in SEQ ID No.2. The vaccine immunization can induce effective respiratory mucosa immune response, meanwhile, humoral immune and cellular immune response are remarkably induced, the safety is high, live pathogens are not involved in the vaccine preparation process, no adverse reaction is generated after immunization, and mucosa immunity can be activated when the vaccine immunizes a body; the required antigen content is obviously lower than that of the existing vaccine, the mucosal immunity is enhanced and the immune duration is prolonged by screening adjuvants, and a good immune protection effect can be provided.

The invention discloses a preparation method and application of an oral chicken infectious anemia vaccine. The preparation method comprises the following steps: providing an eimeria vector; genes of VP1 protein and VP2 protein for coding the chicken infectious anemia virus are introduced into the eimeria vector; after oral immunization, the recombinant eimeria can effectively reduce the clinical symptoms and virus load of chicken lean transmission, saves the manpower and material resources of vaccine immunization, is suitable for prevention and control of poultry epidemic diseases in large-scale breeding industry, and has a wide application prospect.

This invention discloses a subunit vaccine against Echinococcus cantonensis infection and its preparation method; it comprises an immunogen EC95 antigen protein and a pharmaceutically acceptable carrier; wherein the amino acid sequence of the dEC95 protein is as shown in SEQ ID No. 1 or its degenerate sequence. Currently, there is no vaccine against Echinococcus cantonensis infection. This invention uses the dEC95 protein as the antigen, and the prepared subunit vaccine against Echinococcus cantonensis infection has low production cost, simple production process, and many advantages such as safety, high efficiency, and low cost; even when the dEC95 protein antigen content in the anti-Echinococcus cantonensis subunit vaccine is only 40 μg / ml, an antibody titer of over 1:128 can be achieved at week 4 after secondary immunization, and a high antibody titer can be maintained for a long period of time.

This invention relates to the field of bioengineering technology, specifically to a method for preparing neutrophil gelatinase-associated lipid transport protein and its antibody. Specifically, using pET23a(+) as the expression vector, the NGAL gene with six His tags fused to its N-terminus under promoter control is introduced into *E. coli* for induced expression. After purification using a Ni Focurose 6FF column and a molecular sieve column, tag-free NGAL protein with a purity ≥95% is obtained. Subsequently, the NGAL protein is used to repeatedly immunize Japanese rabbits, and serum is collected after each immunization. Qualified serum is screened using a two-dimensional agar diffusion assay, and then purified using the aforementioned antigen to prepare an antigen affinity purification column, yielding a highly active NGAL polyclonal antibody. The high-purity recombinant NGAL of this invention not only possesses activity but is also low-cost, not limited by raw materials, and can be mass-produced, possessing potential and wide-ranging application value in clinical and in vitro diagnostics.

The invention belongs to the technical field of bioengineering, and particularly relates to an Mtb8 polyclonal antibody as well as a preparation method and application thereof. The polyclonal antibody is an Mtb8 specific polyclonal antibody obtained by immunizing an animal with cell wall components of mycobacterium tuberculosis, collecting immunized serum and purifying the serum. The polyclonal antibody is only combined with Mtb8 and only reacts with mycobacteria, so that the polyclonal antibody has relatively good specificity and relatively high sensitivity. The polyclonal antibody prepared by the invention can be used for detecting tuberculosis and nontuberculous mycobacterium (NTM) diseases, and is beneficial to improving the accuracy of a detection result.

This invention belongs to the field of molecular biology technology, specifically relating to an anti-CD28 nanobody, its preparation method, and its application. The preparation process of the anti-CD28 nanobody provided by this invention is as follows: CD28 antigen is constructed to immunize alpacas; a phage library is constructed from the immunized alpaca PBMCs; the phage library is screened, and correct sequences are selected for construction, expression, and purification; the anti-CD28 nanobody is finally obtained after screening by cell function detection. The nanobody provided by this invention has specific recognition and binding ability for CD28, exhibiting advantages such as high specificity and high sensitivity; simultaneously, it effectively reduces the development and production costs of CD28 antibodies and shortens antibody expression time.

The application specifically relates to a 24-gene-deleted attenuated African swine fever virus strain and application as a vaccine. In the ASFV-CN / GS-2018 virus, 24 genes, including KP177R, L83L, L60L, ASFV-G-ACD-00090, ASFV-G-ACD-00120, 285L, ASFV-G-ACD-00160, and MGF-360, MGF-110, MGF-300, MGF-100, are jointly deleted to obtain an attenuated African swine fever vaccine strain; after the attenuated African swine fever vaccine strain immunizes pigs, the pigs are completely attenuated, the immunized pigs are healthy, high-level protective antibodies are detected in the blood of the immunized pigs, and 100% immune protection can be provided to the ASFV CN / GS / 2018 virulent strain attack, so that the attenuated African swine fever vaccine strain can be used as a safe and effective African swine fever candidate vaccine and has great social value.

This invention provides a nanobody targeting carp herpesvirus type II and its application. The amino acid sequence of the nanobody is shown in SEQ ID NO. 1-6. The method includes immunizing alpacas with inactivated carp herpesvirus type II, collecting peripheral blood from the immunized alpacas and separating lymphocytes, and extracting total RNA; synthesizing cDNA by reverse transcription, and amplifying the gene fragment encoding the nanobody; ligating it into the pComb3xss vector, and then transforming it into competent cells to construct a nanobody phage display library; enriching and panning the inactivated virus as a coating antigen to obtain specifically binding phage particles; transforming the selected positive clones into host bacteria for induced expression; and obtaining the anti-carp herpesvirus type II nanobody after separation and purification. This invention aims to provide a carp herpesvirus type II nanobody that is low in expression cost and difficulty, has a stable source, can effectively bind to carp herpesvirus type II, and specifically achieves immunoassay of carp herpesvirus type II.

An inactivated vaccine with the antigen content of 105.0 TCID50 / mL prepared by taking the separated FPV-BJ strain as an immunogen is used for immunization of kittens, a detectable antibody level appears in vivo and presents a rising trend on the 7 day after immunization, a high antibody titer is achieved for the first time on the 21 day, and a high antibody titer is achieved for the second time on the 28 day after secondary immunization. Compared with the prior art, the method has the advantages that the antibody level is greatly increased, the highest average antibody titer of an experimental group can reach 220.5, the complete protection on the existing prevalent strain, namely the FPV-BJ strain and other FPV strains separated by the method can be realized, and relatively, the traditional commercial vaccine cannot provide effective protection on the separated strains.

The invention discloses preparation and application of a dairy cow fibroblast growth factor 21 (FGF21) protein polyclonal antibody, and the preparation method comprises the following steps: constructing a recombinant prokaryotic expression vector PET-28a-FGF21 by using a seamless cloning technology, and successfully expressing a dairy cow FGF21 recombinant protein in escherichia coli; and purifying by nickel column affinity chromatography to obtain high-purity recombinant protein, emulsifying the high-purity recombinant protein and a Freund's adjuvant according to a volume ratio of 1: 1, immunizing 6-8 weeks old female Balb / c mice, and after four times of immunization, taking blood from eyeballs and separating high-titer serum. The polyclonal antibody of the dairy cow FGF21 gene recombinant expression protein prepared by the invention has good specificity, not only can specifically recognize prokaryotic expression products of dairy cow FGF21, but also can specifically recognize endogenous FGF21 proteins in liver tissues of healthy dairy cows and dairy cows with fatty liver; and a material basis is provided for in-vitro quantitative detection of the dairy cow FGF21 and a dairy cow fatty liver diagnosis kit.

The invention discloses a canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine and a preparation method thereof, and relates to the technical field of biological medicines. The canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine takes recombinant proteins rEg 05752 and rEg 09809 as core double antigens, and the recombinant proteins rEg 05752 and rEg 09809 do not have transmembrane regions and signal peptides and contain a plurality of B cell antigen epitopes. After a beagle is immunized, a body can be efficiently induced to generate a specific IgG antibody, the titer of the antibody reaches a peak value 35 days after immunization and still maintains a relatively high level after attack, and meanwhile, Th1 / Th2 type mixed immune response is remarkably activated, so that the levels of cell factors such as IL-2, IFN-gamma, IL-4 and IL-5 are greatly improved. The immune protection effect is remarkable, and a safe and efficient novel technical means is provided for source prevention and control of the cystic echinococcosis.

The present application relates to a kind of echinococcus Eg95 protein, nucleotide and mRNA for coding the protein of the present application.By optimizing echinococcus Eg95 protein amino acid and nucleotide sequence, echinococcus circular RNA vaccine, echinococcus linear mRNA vaccine and echinococcus self-replicating mRNA vaccine are prepared, the vaccine can provide strong immune protection to 4-month-old lambs only one needle immunization, so that it can still obtain more than 80% protection (higher than 70% required by Ministry of Agriculture and Rural Affairs) on the 180th day after immunization, solve the problem that commercial sheep echinococcosis genetic engineering subunit vaccine immunity is weak, and frequent vaccination is needed to obtain immune protection, reduce the repeated burden of vaccine procurement and labor cost, reduce the stress response to sheep flock, improve vaccination coverage and compliance, and be conducive to the prevention and control of our country hydatid disease.

The application discloses a kind of liposome polypeptide vaccine of pulmonary inhalation immunity and its preparation method and application, belong to biological medicine technical field.The vaccine includes the liposome of DSPC and DDAB, polypeptide antigen and molecular adjuvant loaded therein.The optimal preparation process condition is: the mass ratio of DSPC and DDAB 5:1, ultrasonic power 275 W, ultrasonic number 50 times, the liposome particle size obtained is about 100 nm, surface is positive charge, meet the physical property requirement of respiratory mucosa immunity.The vaccine can be widely distributed in lung and long time retention after pulmonary mucosa route immunity, promote the uptake and activation of dendritic cell in lung to antigen, further activate T, B cell, produce mucosal immune response, and be taken up after dendritic cell, transport to lymph node, stimulate systemic adaptive immune response.The application provides effective mucosal immune vaccine platform for the prevention and treatment of respiratory pathogenic microorganism infection.